Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Helsinn Healthcare and Riemser Arzneimittel have expanded their licensing agreement, under which Riemser has got license to commercialize a treatment to prevent chemotherapy-induced nausea and vomiting (CINV) in Germany, which is currently under development by Helsinn.
Subscribe to our email newsletter
The new product is a fixed-dose combination (in both oral and IV forms) containing netupitant, a neurokinin-1 (NK1) receptor antagonist, and palonosetron.
The agreement allows Helsinn to take care of all development activities (CMC, preclinical and clinical), obtaining regulatory approvals, and holding the New Drug Application.
Additionally, Helsinn will also be responsible for the supply of the product for commercial use in Germany.